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Abstract
Background In severely obese type 2 diabetes patients, gastric
bypass surgery (GB) reduces body mass index (BMI) and
hemoglobinA1c (HbA1c) and allows reduced doses of insulin
and other medications. Data regarding the effects of GB on
severely obese patients with type 1 diabetes are limited.
Methods Severely obese women with type 1 diabetes (n=9)
were studied immediately before and after GB (7.7±5.8 weeks,
mean ± SD).
Results On average, GB reduced mean BMI by 11 % and
mean HbA1c by 0.9 % (from 8.0 to 7.1 %), with a parallel
38 % decrease in basal insulin requirements (expressed per
kilogram of body weight).
Conclusion GB rapidly decreased BMI, HbA1c, and insulin
requirements in severely obese women with type 1 diabetes.
However, physiologic insulin replacement remains necessary
in patients with type 1 diabetes.
Keywords Gastric bypass surgery . Type 1 diabetes . Insulin
requirements
Background
Recent data demonstrate that gastric bypass surgery (GB) is a
highly effective strategy for the treatment of type 2 diabetes.
GB achieves long-term weight loss, decreases mortality [1],
and rapidly normalizes hyperglycemia [2], permitting dosage
reduction and/or withdrawal of diabetes medication. These
effects are likely related to both the marked reduction in
peripheral insulin resistance [3] and increased incretin and
insulin secretion [4], which occur even prior to sustained
weight loss [5–7].
By contrast, little is known about the effects of GB on
severely obese patients with type 1 diabetes. Prior case reports
showed mixed effects of GB on hemoglobin A1c (HbA1c)
and insulin requirements in individuals with type 1 diabetes
[8–11]. Given the limited studies in this increasingly obese
population [12], we investigated the short-term effects of GB
on weight, HbA1c, and insulin requirements in obese subjects
with type 1 diabetes.
Methods
Study Population
The study was approved by the Institutional Review Board of
the Joslin Diabetes Center, and informed consent was waived.
The electronic medical record database of the Joslin Diabetes
Center was queried for the terms “type 1 diabetes” and “gas-
tric bypass” for visits which occurred between January 1,
2000 and April 1, 2012; a total of 27 individuals were found.
Gastric bypass was defined as Roux-en-Y laparoscopic gastric
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bypass surgery. After excluding subjects without a date
of surgery listed (14.8 %), not on insulin therapy
(3.7 %), with missing pre- or postsurgery visit documenta-
tion, or a visit >20 weeks after surgery (48.1 %), nine indi-
viduals were included in the final cohort for analysis. Demo-
graphic data were collected from medical records.
Subjects were treated with either continuous subcutaneous
insulin infusion (CSII) or multiple daily injections (MDI). For
CSII-treated subjects, only the basal insulin contribution to the
total daily dose of insulin was available for review. For MDI-
treated subjects, basal and meal bolus insulin requirements
were recorded. Medical records were reviewed in detail to
confirm the diagnosis of type 1 diabetes based on clinical
characteristics [13]. The diagnosis of type 1 diabetes was
further supported by the presence of autoantibodies against
glutamic acid decarboxylase (GAD), insulinoma-associated
(IA-2), and insulin (IAA), and/or low or undetectable C-
peptide levels in four out of four patients tested. Additionally,
patients were diagnosed with type 1 diabetes at a mean age of
15 years (<12 years of age in 56 % of subjects).
Data Analysis
Bodymass index (BMI), HbA1c, and basal insulin doses were
considered primary outcomes. Systolic and diastolic blood
pressures were considered secondary outcomes. BMI was
calculated as weight in kilogram/height in square meters.
HbA1c values were collected from medical record data. Insu-
lin requirements were expressed relative to body weight and
presented as units per kilogram per day, and both absolute and
relative differences between pre- and postoperative require-
ments were calculated.
Table 1 Baseline characteristics
and postsurgery changes
Values are represented as mean ±
SD. Baseline characteristics of
type 1 diabetes subjects who
underwent GB were obtained
during the last presurgery visit.
HbA1c, BMI, blood pressure, and
insulin requirements were obtain-
ed during the first postsurgical
visit (mean 7.7±5.8 weeks) and
the last presurgical visit
TDD total daily dose,MDI multi-
ple dose injections
Presurgery Postsurgery p values
Age at time of surgery (years) 40.3±8.5
Female sex—N (%) 9 (100)
Height (cm) 167.8±8.0
Weight (kg) 122.2±23.5
Diabetes duration at time of surgery (years) 25.3±8.9
Mean age at DM diagnosis (years) 15.0±8.2
Low or undetectable C-peptide level—N (%) 4 (44 %)
Autoantibodies present (GAD, IA2, IAA)—N (%) 3 (33 %)
Insulin pump—N (%) 5 (56 %)
Insulin pump and pramlintide 1 (11 %)
Multiple daily injections—N (%) 4 (44 %)
Multiple daily injections and metformin 1 (11 %)
Supplemental medications—N (%) 2 (22 %)
Pramlintide, metformin
HbA1c (%) 8.0±1.3 7.1±0.9 <0.05
BMI (kg/m2) 43.8±8.0 38.7±8.6 <0.05
Basal insulin requirement (U/day) 59.7±43.8 32.6±20.9 <0.05
% Basal insulin compared to presurgery (n=9) N/A 54.6
Basal insulin/kg/day (U/kg/day) 0.47±0.28 0.29±0.14 <0.05
% Basal insulin/kg/day compared to presurgery N/A 61.8
Meal bolus insulin requirement (U/day) (n=4) 53.0±27.3 18.1±12.6 0.061
% bolus insulin compared to presurgery N/A 40.1
Meal bolus dose/kg/day (U/kg/day) 0.44±0.24 0.15±0.09 0.076
% bolus insulin/kg/day compared to presurgery N/A 34.6
Total daily insulin requirement (U/day) (n=4) 113±33.8 52.6±28.2 <0.05
% TDD compared to presurgery N/A 46.9
Total daily dose/kg/day (U/kg/day) 0.93±0.14 0.51±0.26 <0.05
% TDD insulin/kg/day compared to presurgery N/A 50.7
Systolic blood pressure (mmHg) 124.0±8.7 113.7±22.0 0.14
Diastolic blood pressure (mmHg) 74.2±7.4 67.3±6.0 0.06
Supplemental medications—N (%) 2 (22 %) 0 (0 %)
Assessment postsurgery (weeks) 7.7±5.8
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Age, age at diagnosis, length of time with diabetes, height,
weight, and blood pressure were considered as continuous
variables, and mean and standard deviation were calculated.
Treatment with auxiliary oral or injected diabetes medications
was assessed. To determine whether our primary outcomes
differed before and after GB, we conducted paired t tests and
defined significance as p<0.05. To compare the change in
insulin dose with the change in weight, we used the Pearson
correlation. Microsoft® Office Excel® 2007 was used for
statistical analyses.
Results
All subjects (n=9) were female (mean age 40.3±8.5 years)
and had a mean duration of type 1 diabetes of 25.3±8.9 years
(range 17–46 years). The mean age at diagnosis was 15.0±
8.2 years (range 8–28 years) (Table 1). All subjects were
treated with insulin; five patients used CSII, while four pa-
tients used MDI. Two subjects were also treated with metfor-
min and pramlintide as adjunctive medications to promote
weight loss [14]; both of these subjects had positive autoanti-
bodies and low or undetectable C-peptide levels, confirming
type 1 diabetes.
At the time of the first postsurgical visit (mean 7.7±
5.8 weeks, range 2–18 weeks), BMI had decreased by a mean
of 11 % (from 43.4±8.0 to 38.7±8.6 kg/m2, p<0.05). HbA1c
also decreased significantly, from 8.0 to 7.1 % (p<0.05). The
dose of basal insulin, calculated from recorded CSII and MDI
regimens, decreased from 59.7±43.8 to 32.6±20.9U/day
(p<0.05) (Table 1) and was also significantly decreased when
expressed per kilogram of body weight (38 % reduction, from
0.47±0.28 to 0.29±0.14U/kg/day, p<0.05) (Fig. 1, Table 1).
In MDI-treated subjects (n=4), the meal bolus dose showed a
trend towards a decrease by 65 % (from 0.44±0.24 to 0.15±
0.9 U/kg/day, p<0.08). Similarly, total daily insulin dose in
MDI-treated patients, calculated from recorded basal and bolus
regimens, decreased by amean of 53% from 113±33.8 to 52.6
±28.2 U/day. Total daily insulin dose per kilogram of body
weight also decreased by 49 % from 0.93±0.14 to 0.49±
0.19 U/kg/day (p<0.05). Subjects with postsurgical visits at
<7.7 weeks showed a greater decrease in basal insulin require-
ment than those assessed at >7.7 weeks (−0.23±0.19 vs. −0.11
±0.12 U/kg/day, respectively), but less weight loss (−10.2±7.0
vs. −16.8±10.1 kg, respectively). There was no statistically
significant correlation between the extent of weight loss and
percentage change in basal insulin requirements (Pearson cor-
relation coefficient r=0.34, p=0.37).
None of the subjects was able to discontinue insulin ther-
apy, consistent with their absolute insulin deficiency and type
1 diabetes, but all auxiliary oral and injectable therapy was
discontinued after surgery. Both systolic and diastolic blood
pressure tended to decrease, from 124±9 to 114±22 mmHg
and from 74±7 to 67±6 mmHg (p=0.14 and p=0.06,
respectively).
Discussion
This study demonstrates that GB rapidly and significantly
reduces BMI, HbA1c, and insulin requirements in severely
obese women with type 1 diabetes. These patterns are similar
to those in prior studies of patients with type 2 diabetes [15].
However, the 38 % reduction in basal insulin requirements in
both CSII and MDI-treated patients with type 1 diabetes and














Fig. 1 Basal insulin requirements
per day (U/kg/day) from
individual study participants
(n=9) were determined at the
final presurgical and first
postsurgical visits, between
January 1, 2000 and April 1, 2012
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patients are less than the overall 79 % reduction of insulin
therapy previously observed in studies of type 2 diabetes
patients, although this reduction was reported for a mean
follow-up of 19.7 months [16]. This likely reflects the
persisting absolute requirement for insulin therapy in patients
with type 1 diabetes, as a result of immunological β-cell
destruction and absolute insulin deficiency.
Previous case reports have described mixed effects of GB
on type 1 diabetes. Czupryniak et al. found marked decreases
in insulin requirements and HbA1c after GB in three patients
who had poorly controlled type 1 diabetes preoperatively
(mean HbA1c 10.4 %) [8, 10]. By contrast, a report from
Mendez et al. in three patients showed no significant improve-
ment in HbA1c, despite significant weight loss in three pa-
tients [9]. These differences could be due to the small sample
size or differences in age, gender, time of subject assessment,
and variable preoperative glycemic control. A recent paper
assessed six patients undergoing a variety of bariatric surgical
procedures, finding reductions in weight, insulin require-
ments, and HbA1c 1 year postoperatively; only two of these
patients had undergone GB surgery [11].
In type 2 diabetes, GB improves insulin sensitivity, as
defined by hyperinsulinemic euglycemic clamps [17], in par-
allel with reduced basal insulin levels and increased postpran-
dial insulin secretion [6]. In type 1 diabetes, endogenous
insulin levels are low to absent secondary to autoimmune beta
cell destruction. Thus, the reduction in exogenous basal insu-
lin requirement is likely related to resolution of obesity-
induced insulin resistance. Additionally, reductions in total
caloric intake and or altered proportions of macronutrients
may also contribute to reduced insulin requirements. In our
study, the reduction in basal insulin requirements did not
correlate with the amount of weight loss, suggestive of a
weight loss-independent mechanism. Moreover, GB yields
marked effects on hepatic glucose metabolism as early as
1 week postoperatively, and although these data are derived
from studies of individuals with type 2 diabetes [18], we
hypothesize that similar effects could also be observed in
severely obese patients with type 1 diabetes.
This study has several limitations. First, this is a small
study of nine subjects, and the diagnosis of type 1 diabetes
was defined clinically. However, five of nine subjects were
diagnosed at <12 years of age, and laboratory confirmation
was available in four subjects, including low or undetectable
C-peptide levels and positive autoantibodies. Second, we
assessed the impact on basal insulin levels in all subjects and
meal bolus and total daily insulin doses as reported for MDI
regimens, but we were unable to fully assess prandial doses in
CSII-treated patients, since only insulin-to-carbohydrate ratios
were reported. Third, our cohort was all female; while this is
consistent with the preponderance of females undergoing
bariatric surgery, these findings may not extend to men with
type 1 diabetes who are treated with GB [7].
Despite these limitations, the present study is the largest to
date which evaluates weight loss, glycemic control, and short-
term changes in insulin requirements in patients with type 1
diabetes following GB. We specifically chose to follow sub-
jects at short term (<20 weeks), to assess their insulin require-
ments before more major weight loss occurs and to provide
guidance to clinicians who see these patients during the im-
mediate postoperative and short-term follow-up visits after
surgery. Further studies are clearly required to assess the
durability of weight loss and improved glycemic control in
patients with type 1 diabetes. Moreover, GB markedly alters
patterns of early postprandial glycemia [4], contributing to a
potential mismatch between nutrient absorption and timing of
prandial insulin, with risk of subsequent hypoglycemia. Thus,
it is often challenging to optimize prandial insulin therapy in
post-GB patients. Additional studies will be required to deter-
mine optimal dose and timing of prandial insulin replacement
in post-GB patients in the clinical setting.
In conclusion, we demonstrate that GB decreases BMI,
HbA1c, and insulin requirements in severely obese women
with type 1 diabetes. Consistent with the absolute requirement
for insulin in type 1 diabetes, none of the subjects was able to
discontinue insulin. Continuing an insulin regimen with post-
GB patients with type 1 diabetes is critical in order to prevent
onset of diabetic ketoacidosis, and frequent postoperative
follow-up for adjustment of prandial insulin requirements is
absolutely required. Longitudinal assessment will be impor-
tant to evaluate long-term metabolic changes in our study
population. Future larger and prospective studies will be
needed to confirm these findings, assess the underlying met-
abolic changes, and evaluate the impact of GB on long-term
morbidity and mortality in type 1 diabetes.
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